MCM
NGNE icon

Moore Capital Management’s Neurogene NGNE Stock Holding History

Moore Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.45M Buy
+141,636
New +$3.9M 0.07% 255
2020
Q4 		– Sell
-1,000
Closed -$240K – 576
2020
Q3 		$240K Buy
+1,000
New +$242K ﹤0.01% 341

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Moore Capital Management's NGNE Position: Q2 2026 in Review

Moore Capital Management opened a new position in Neurogene (NGNE) in Q2 2026: 141,636 shares worth $4.45M. The stake represents 0.07% of the portfolio and ranks #255 among its holdings. This is a return to the name: Moore Capital Management previously reported a position in NGNE as recently as Q3 2020.

Moore Capital Management first reported a position in NGNE in Q3 2020 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Moore Capital Management held 141,636 shares of Neurogene worth $4.45M as of Q2 2026.
  • Neurogene was a new Moore Capital Management position in Q2 2026.
  • Neurogene made up 0.07% of Moore Capital Management's portfolio in Q2 2026, its #255 holding.
  • Moore Capital Management first reported a position in Neurogene in Q3 2020 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.